The role of tigecycline in the treatment of infections in light of the new black box warning

@article{Dixit2014TheRO,
  title={The role of tigecycline in the treatment of infections in light of the new black box warning},
  author={Deepali Dixit and Rani Patel Madduri and Roopali Sharma},
  journal={Expert Review of Anti-infective Therapy},
  year={2014},
  volume={12},
  pages={397 - 400}
}
Tigecycline is an antibiotic with a broad spectrum of activity. Similar to tetracycline antibiotics, tigecycline exerts bacteriostatic activity. Earlier studies documented the safety and efficacy of tigecycline for complicated intra-abdominal and complicated skin and skin-structure infections, which led to its approval. Recent systematic reviews and meta-analyses have suggested increased risk of death in patients receiving tigecycline compared to other antibiotics. The Food and Drug… Expand
Re-defining tigecycline therapy.
TLDR
Patients who may be treated with monotherapy, according to the official indications and dosages, from those treated with combination treatment, mostly with high dosages in the setting of nosocomial IAIs, possibly caused by MDR bacteria or as a carbapenem-sparing strategy are distinguished. Expand
A Survey of Clarithromycin Monotherapy for Patients with MAC Lung Disease in Japan
Background: Multi-drug Resistant (MDR) pathogen Carbapenem-Resistance Klebsiella pneumonia (CR-Kp) associated Ventilator-Associated Pneumonia (VAP) is a serious infectious disease and tigecyclineExpand
Increasing frequency of Pseudomonas aeruginosa infections during tigecycline use.
TLDR
The results contribute to the need for new studies to determine the safety of tigecycline use, especially for the treatment of critically ill patients, and rational use of this antibiotic in ICU patients is essential. Expand
Safety and Efficacy of Tigecycline in ICU Patients Based on Therapeutic Drug Monitoring.
TLDR
Cmin can be a useful predictor of hepatotoxicity with a cut-off of 474.8 ng/mL in ICU patients treated with tigecycline and it is at risk of high exposure in female. Expand
Beyond Susceptible and Resistant, Part III: Treatment of Infections due to Gram-Negative Organisms Producing Carbapenemases.
TLDR
Treatment of CRE infections in children is particularly challenging because therapeutic options for CRE lack adequate data on dosing and safety in children, and use of unconventional combination treatment regimens, including agents to which the organism is resistant in vitro, may provide some benefit in the treatment of severe CRE infection. Expand
Genetics, Epidemiology and Clinical Manifestations of Multidrug-Resistant Acinetobacter baumannii.
  • P. Nasr
  • Medicine
  • The Journal of hospital infection
  • 2019
TLDR
Trends in epidemiology, genetic markers, and other factors that influence the incidence of multidrug-resistant A. baumannii are described. Expand
Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections
TLDR
Zidovudine was shown to be the most promising candidate for use in combination with Tigecycline to treat systemic CRE infections, and should involve the use of animal infection models. Expand
Is it time to move away from polymyxins?: evidence and alternatives.
TLDR
Recently approved cefiderocol and phase 3 stage combination drug cefepime-zidebactam assume greater significance due to their potential to act as polymyxin-supplanting therapies in treating carbapenem-resistant infections. Expand
Tigecycline salvage therapy for critically ill children with multidrug-resistant/extensively drug-resistant infections after surgery.
  • Ying Song, Lei Hu, +4 authors L. Tan
  • Medicine
  • International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • 2018
TLDR
Tigecycline salvage therapy was successful in 86% of critically ill pediatric patients with MDR/XDR infections after surgery, with no severe adverse effects. Expand
Pharmacokinetic and Pharmacodynamic Considerations of Antibiotics of Last Resort in Treating Gram-Negative Infections in Adult Critically Ill Patients
TLDR
Patients with resistant gram-negative infections may present with septic shock in the ICU and require dosage adjustments to attain optimal drug levels, which will help to maximize therapeutic efficacy while minimizing toxic effects. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 34 REFERENCES
Tigecycline for the Treatment of Acinetobacter Infections: A Case Series
TLDR
Most patients received tigecycline therapy for the treatment of infections caused by Acinetobacter spp. Expand
Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens.
TLDR
Tigecycline represents a promising option in infections from MDR pathogens, however, further clinical experience is required. Expand
Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis.
TLDR
Tigecycline is not better than standard antimicrobial agents for the treatment of serious infections, and assessment with unpublished studies is needed to make appropriate decisions about new agents. Expand
Tigecycline is efficacious in the treatment of complicated intra-abdominal infections.
TLDR
TGC is efficacious in the treatment of patients with cIAIs and TGC met per the protocol-specified statistical criteria for noninferiority to the comparator, IMI/CIS. Expand
Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease
TLDR
Evidence is provided that tigecycline monotherapy may be used as effectively as the comparison therapy for cSSSI, cIAIs, CAP, and infections caused by MRSA/VRE, and prudence with the clinical use of tigECyclines monotherapy in infections is required. Expand
Tigecycline: a new glycylcycline antimicrobial agent.
  • N. Kasbekar
  • Biology, Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2006
TLDR
Tigecycline is an alternative agent available for the treatment of resistant gram-negative and gram-positive infections, especially in patients with a history of a penicillin allergy or antimicrobial-related toxicities. Expand
Efficacy and safety of tigecycline: a systematic review and meta-analysis.
TLDR
Clinicians should avoid tigecycline monotherapy in the treatment of severe infections and reserve it as a last-resort drug. Expand
Tigecycline: what is it, and where should it be used?
  • D. Livermore
  • Biology, Medicine
  • The Journal of antimicrobial chemotherapy
  • 2005
TLDR
Tigecycline is the first glycylcycline to be launched and is one of the very few new antimicrobials with activity against Gram-negative bacteria, likely to find a role in the treatment of infections due to multiresistant pathogens. Expand
The emergence of clinical resistance to tigecycline.
TLDR
Tigecycline should be cautiously used in the clinic, and efflux-mediated resistance should be closely monitored in order to prolong the lifespan of this useful antibiotic. Expand
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
TLDR
Overall, the tigecycline regimen was noninferior to the imipenem/cilastatin regimen for the c-mITT but not the CE population; this difference appears to have been driven by results in VAP patients. Expand
...
1
2
3
4
...